Clinical-stage biotechnology company Freeline Therapeutics has announced a modification to the clinical development plan for its FLT180a programme for Hemophilia B.

The latest development will address the US Food and Drug Administration (FDA) feedback on the characterisation and comparability of the investigational drug product used in its Phase I / II B-AMAZE trial.

It was produced at smaller scale versus its current investigational drug product manufactured at a commercial scale.

As per the modified clinical development plan, Freeline intends to carry out dose confirmation in an FLT180a Phase I / II trial instead of in the Phase IIb part of the previously planned Phase IIb / III pivotal trial.

The company hopes that the modification should aid in meeting its objectives of initiating the clinical trial sites for the dose confirmation trial by the year-end.

Parallelly, it will work to meet FDA’s Chemistry, Manufacturing and Control (CMC) requirements ahead of the start of Phase III pivotal trial.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The six-month Phase I / II dose confirmation trial will analyse the safety and efficacy of a single-dose drug to confirm the dose and immune management regimen for the planned Phase III pivotal trial.

As per data from dose-ranging B-AMAZE trial, a dose of FLT180a between 7.5e11 and 9.75e11vg / kg1 could potentially bring patients into the normal range of Factor IX (FIX) activity level of 50-150%, the company noted.

Freeline Therapeutics CEO Theresa Heggie said: “We believe conducting dose confirmation in a Phase I/II trial should allow us to achieve similar objectives as our previously planned trial, whilst also enabling us to work with FDA on CMC before initiating the Phase III pivotal trial.

“To streamline the development path for our subsequent programmes, we have developed our entire pipeline from Phase I onward using the same commercial-scale manufacturing platform that we are now using for FLT180a.”

Freeline expects a data readout for the Phase I / II dose confirmation trial by next year-end, the Phase III pivotal trial commencement by mid of 2023 and filing of a Biologic License Application (BLA) with the FDA by 2024-end.